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Hypoxia inducible factor-1 (HIF-1) is a key regulator in hypoxia and can determine the fate
of brain cells during ischemia. However, the mechanism of HIF-1 regulation is still not fully
understood in ischemic brains. We tested a hypothesis that both the 26S and the 20S
proteasomal pathways were involved in HIF-1α degradation under ischemic conditions.
Using in vitro ischemic model (oxygen and glucose deprivation) and a mouse model
of middle cerebral artery occlusion, we tested effects of inhibitors of proteasomes and
prolyl hydroxylase (PHD) on HIF-1α stability and brain injury in cerebral ischemia. We
observed that 30 and 60min of oxygen-glucose deprivation significantly increased the
20S proteasomal activity. We demonstrated that proteasome inhibitors increased HIF-1α
stabilization and cell viability and were more effective than PHD inhibitors in primary
cultured cortical neurons exposed to oxygen and glucose deprivation. Furthermore, the
administration of the proteasome inhibitor, epoxomicin, to mice resulted in smaller infarct
size and brain edema than a PHD inhibitor. Our results indicate that 20S proteasomes
are involved in HIF-1α degradation in ischemic neurons and that proteasomal inhibition
provides more HIF-1α stabilization and neuroprotection than PHD inhibition in cerebral
ischemia.
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INTRODUCTION
Hypoxia inducible factor 1 (HIF-1), a transcription factor, is considered to be the most critical
factor involved in the cellular response to hypoxia. This is mainly due to its regulation of 1–2%
of human genes that play important roles in cellular adaptation to low oxygen (Mazure et al.,
2004). HIF-1 is a heterodimeric protein formed by a continuously expressed subunit HIF-1β and
an oxygen regulated subunit HIF-1α (Wang et al., 1995a). Under normal oxygen levels, HIF-1α is
degraded through the ubiquitin-dependent proteasomal (26S) pathway. In order for a protein to
be targeted to the 26S proteasome, it requires a poly-ubiquitin tail that can be detected by the 19S
for subsequent processing and unfolding. It is known that von Hippel-Lindau tumor suppressor
(pVHL) possesses ubiquitin ligase E3 activity that attaches ubiquitin to HIF-1α protein. To be
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recognized by pVHL, HIF-1α needs to be hydroxylated by
prolyl hydroxylases (PHD), which uses oxygen as a co-substrate
and hydroxylate two proline residues (Pro402 and Pro564).
During hypoxia, HIF-1α is stabilized in cells due to reduced
hydroxylation. However, low oxygen does not guarantee an
increase in the level of HIF-1α protein. For example, HIF-1α
levels were very low in hypoxic neurons in the absence of glucose.
Themechanism responsible for low expression of HIF-1α in these
conditions remains unclear.
The proteasomal proteolytic pathways are the main
mechanisms responsible for the degradation of abnormal
or unwanted proteins, which contain 26S and 20S proteasomal
pathways. The 26S proteasome is the most abundant form
and is composed of a 20S catalytic core and two regulatory
19S caps (Coux et al., 1996). The 20S proteasome complex
can exist on its own and unlike the 26S proteasome it does
not target ubiquitinated proteins but may act on oxidized
proteins (Coux et al., 1996). Although, both the 26S and 20S
can degrade oxidized proteins, many studies have determined
that the contribution of the 20S is significantly higher (Davies,
2001; Breusing and Grune, 2008; Jung and Grune, 2008). Since
HIF-1α contains residues with redox properties such as cysteine
and methionine, it is an oxidizable protein (Huang et al., 1996,
1998). This potentially makes HIF-1α a target for degradation
by the 20S proteasome in an oxidizing environment. Indeed,
Kong et al. reported that HIF-1α’s turnover under hypoxia was
possibly regulated by the ubiquitin-independent proteasomal
(20S) degradation pathway (Kong et al., 2006, 2007).
Ischemia is characterized by an increase in reactive oxygen
species (ROS) formation. We hypothesized that both the
ubiquitin-dependent (26S) and the ubiquitin-independent (20S)
proteasomal pathways contribute to HIF-1α degradation during
ischemia. To test the hypothesis, we assessed effects of ischemia
on the 26S and 20S proteasomal activities, evaluated the
contribution of the proteasomal pathways to HIF-1α degradation
during hypoxia, and determined the effect of HIF stabilization
through proteasomal inhibition on neuronal viability and brain
damage in in vitro and in vivo ischemia models. To our
knowledge, this is the first study to examine the contributions of
both 20S and 26S proteasomal pathways to HIF-1α degradation
and neuronal injury during cerebral ischemia with in vitro and in
vivo models. Our results demonstrated that the 20S proteasomal
activity was increased by ischemia. Furthermore, the results
confirmed a role of the 20S in HIF-1α degradation.
EXPERIMENTAL PROCEDURES
Culture of SH-SY5Y Cells and Primary
Cortical Neurons
SH-SY5Y cells were cultured in Dulbecco’s Modified Eagle’s
Medium (DMEM) with 10% fetal bovine serum (FBS)
and antibiotics (penicillin-streptomycin 1:100) at 37◦C in a
humidified incubator gassed with 95% air and 5% CO2. Primary
neurons were prepared from the cortical tissues of Sprague–
Dawley rat brains at embryonic day 16 [E16] to E18 (Guo
et al., 2008). Experiments were conducted 10–12 days following
dissection. The University of Kansas Institutional Animal Care
and Use Committee approved all procedures.
Assessment of Proteasomal Activities
Proteasomal activity was measured as described previously
(Fekete et al., 2005). Briefly, cells were washed with PBS (pH 7.4)
and then lysed by 2 freeze-thaw cycles in a lysis buffer [25mM
HEPES (pH 7.8), 0.25M sucrose, 10mM MgCl2, 1mM EDTA,
and 1mM dithiothreitol (DTT)]. The lysates were centrifuged at
11,000 RPM at 4◦C for 30min. Cell lysate proteins (10µg) were
incubated with 100µL of proteasome activity assay buffer. The
assay buffer for evaluation of 26S proteasome function consisted
of 50mM Tris (pH 7.4), 5mM MgCl2, 2mM DTT, 2mM
ATP, and the fluorogenic substrate Suc-LLVY-AMC (80µM in
1% DMSO, Sigma-Aldrich). The buffer for determining 20S
proteasome function contained 20mMHEPES (pH 7.8), 0.5mM
EDTA, 0.03% SDS, and 80µM Suc-LLVY-AMC. The assays
monitor the hydrolysis of Suc-LLVY-AMC into AMC (7-amino-
4-methly-coumarin), which is then detected with a fluorescence
plate reader at ex 380 nm and em 440 nm.
Biochemical Protein Degradation
Plasmid cDNA of HIF-1α was transfected to SY5Y cells. Cell
extracts prepared in modifiedM2 buffer was incubated with anti-
HIF-1α antibody and protein A-sepharose beads (Pharmacia)
at 4
◦
C overnight. The beads were precipitated and washed five
times with M2 buffer. One tenth of the beads were used to verify
the bound HIF-1α protein. Western blot for the proteasome
20S subunits (antibodies: Santa Cruz, 1:1,000) was included to
confirm no contamination of the proteasomes. The protein on
beads was incubated with H2O2 (0.03%) and Fe
2+ (0.1mM) in
DMEM for 3 h. Precipitated HIF-1α protein with or without
oxidation by H2O2 were incubated with 20S proteasome (Boston
Biochem) to determine the proteasome’s ability to degrade HIF-
1α. To determine the ability of 26S proteasome, the precipitated
HIF-1α was incubated with a cytosol fraction from SH-SY5Y
cells and 26S proteasome (Boston Biochem). After HIF-1α was
incubated with the proteasomes for 1 and 3 h, Western blotting
was carried out to determine the level of HIF-1α. MG-132 was




Oxygen-glucose deprivation (OGD) was used as an in vitro
ischemia model, which mimics the loss of oxygen and glucose
that occur in a stroke when blow flow is blocked. Cells were
incubated in the absence of glucose with 1% O2 at 37
◦C
in a humidified hypoxia chamber (Coy laboratory products).
Neuronal viability was assessed using the MTT [3-(4,5-
dimethylthiazol-2-yl) 2,5-diphenyl tetrazolium bromide] assay
kit (Invitrogen). To inhibit proteasomes and PHD activity, cells
were pre-treated for 60min with the proteasome inhibitors MG-
132 (10, 40, and 80µM) and epoxomicin (Epox, 8µM) from
Boston Biochem. Prolyl hydroxylases were inhibited with 2mM
dimethyloxalylglycine (DMOG).
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In vivo
Brain ischemia was induced using the well-established middle
cerebral artery occlusion (MCAO) model in mice (Clark et al.,
1997). The University of Kansas Institutional Animal Care and
Use Committee approved all in vivo brain ischemia studies
(protocol #191). Anesthesia for the mice was induced with
3% isoflurane and maintained with 1.5% isoflurane throughout
the procedure. Buprenorphine was used as the analgesic and
was injected pre-operatively at 0.05mg/kg. Twenty to twenty-
five grams C57/Bl/6 male mice were subjected to MCAO
followed by a 24 h period of reperfusion. To inhibit proteasomes
and PHD activity, DMOG (50mg/kg/0.1 cc, i.p.) and/or Epox
(1.1mg/kg/0.1 cc, i.p.) in DMSO were administered to mice
24 h before MCAO. TTC (2,3,5-triphenyltetrazolium chloride
monohydrate) staining was used to assess brain damage (Ito et al.,
1997). The corrected infarct area was calculated as previously
described (Schäbitz et al., 1999). Brain edema volume (Vedema)
was also measured from the coronal sections that were stained by
TTC by determining the volumes of both the ipsilateral (affected)
hemisphere (VIpsi) and the contralateral hemisphere (Vcontra)
and using the equation: Vedema =Vcontra −VIpsi (Yan et al., 2011).
The final analyses of the different treatments and animal groups
were performed in a blinded fashion.
Immunoblot Analysis
Cells were lysed in 200µL RIPA buffer (ThermoScientific)
and the protease inhibitor cocktail kit (Thermo Scientific) and
scraped using a cell lifter (Biologix Research Company). The
lysates were centrifuged at 12,000 RPM for 10min at 4◦C and
the protein concentration of the supernatants was determined
using a protein assay kit (Bio-Rad). Proteins were separated
by SDS–PAGE and the separated proteins were transferred to
a nitrocellulose membrane (BIO-RAD). After being blocked
with 5% nonfat milk in Tris-buffered Saline with Tween (TBST
the membrane was incubated with the anti-HIF-1α rabbit
monoclonal (1–1,000; 04–1,006; Millipore) or the anti-hydroxyl-
HIF rabbit polyclonal (1–1,000; NB110-74679 Novus) primary
antibody overnight at 4◦C and the secondary antibody (1–3,000;
goat anti rabbit IgG-horseradish peroxidase; sc-2030 Santa Cruz)
for 1 h at RT. Western blots were quantified using ImageJ
software and protein levels were normalized to β-actin.
Data and Statistical Analysis
Data are presented as means ± SEM from a minimum of three
independent experiments. One-way ANOVA followed by Tukey’s
multiple comparisons test and the Student’s t-test were used for
overall significance. Differences of p < 0.05 were considered
statistically significant. GraphPad Prism software, Image-Pro
Plus 5.1 (Media Cybernetics), ImageJ, and Excel were used for
data analyses.
RESULTS
In vitro Ischemia Elevated Proteasomal
Activity in Neurons
We first evaluated the effects of ischemia on proteasomal activity
in neurons. Primary cortical neurons were exposed to OGD
for 30, 60, and 90min and then the activities of the 26S and
20S proteasome were assessed and compared to neurons at
control conditions. Following OGD treatment, there was a mild
increase in 26S activity however it was not statistically significant
(Table 1). On the other hand, 20S activity was significantly
increased after 30 or 60min exposure to OGD. The activity began
to decrease after 60min. Since ischemia is characterized by an
increase in ROS (Moro et al., 2005) we also determined the
effect of KO2 generating superoxide anion radical and H2O2 on
proteasomal activity in SH-SY5Y cells (Supplementary Figure 1).
Our results indicated that ROS can also increase both 20S and 26S
activities dependent on its concentration.
20S Proteasomes Were Able to Degrade
HIF-1α in a Biochemical System
We investigated the effect of 20S on the level of HIF-1α
protein at elevated ROS conditions in a biochemical system.
As shown in Figure 1, H2O2 treatment alone had no effect
on the level of HIF-1α protein. 20S proteasomes efficiently
degraded HIF-1α protein exposed to H2O2 for 1 or 3 h while
26 proteasomes had little effect on the level of HIF-1α. The
figure also demonstrates that in the presence of ubiquitin,
TABLE 1 | Effect of oxygen-glucose deprivation on 26S and 20S
proteasomal activity in primary cortical neurons.
OGD duration (min) Proteasomal activity (% of control)
26S 20S
0 100 100
30 106.9 ± 5.5 104.8 ± 2.5*
60 107.1 ± 3.9 114.4 ± 4.1*
90 105.2 ± 2.8 100.5 ± 5.5
Primary cortical neurons were exposed to oxygen and glucose deprivation (OGD) for 30,
60, or 90 min and then the 26S and 20S proteasomal activity was determined from the
lysates. The increase in the 20S proteasome activity following both 30 and 60 min OGD
exposure was found to be significant. *p < 0.05 vs. 0 min (n = 3).
FIGURE 1 | HIF-1α degradation by the 20S proteasomes. Immunoblotting
for HIF-1α after the HIF-1α protein-beads were incubated with a cytosol
fraction from SH-SY5Y cells and either the 26S or 20S proteasome for 1 and
3 h with the addition of (A) H2O2 or (B) ubiquitin.
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26 proteasomes readily degraded native HIF-1α whereas 20S
proteasomes had no effect on the level of HIF-1α. The results
indicate that 20S and 26S proteasomes prefer degrading oxidized
and native HIF-1α protein, respectively.
Both 20S and 26S Proteasomes
Contributed to HIF-1α Protein Degradation
In vitro
The above results suggested that both 20S and 26S proteasomes
could degrade HIF-1α although they preferred different modified
forms of the protein. To determine the contributions of both 20S
and 26S proteasomal pathways to the degradation of HIF-1α in
ischemic neurons, we carried out experiments in the presence
of proteasome inhibitors or PHD inhibitors. As hydroxylation
is a required step for HIF-1α to be degraded through the
26S degradation pathway but not the 20S pathway, PHD
and proteasomal inhibitions would differentiate the individual
contribution of the two pathways to HIF-1α degradation. MG-
132 and DMOG were used to inhibit proteasomes and PHD,
respectively. As Figure 2 shows, OGD for 60min increased the
HIF-1α level in primary cultured cortical neurons. Pretreatment
of MG-132 at 10µM further elevated HIF-1α level (149%
increase, compared to OGD only). MG-132 at 40 and 80µM
induced a 172 and 174% increase in the level of HIF-1α over
OGD only, respectively. A smaller increase in the HIF-1α level in
the presence of higher level of MG-132 indicated that at a level
of 10µM MG -132 was able to effectively inhibit proteasomal
activity.
DMOG was also able to further increase the HIF-1α
level, indicating that even under low oxygen conditions, 26S
proteasomal pathway was involved in degrading HIF-1α protein.
We observed a 57% increase in the HIF-1α protein level in
cells pretreated with 0.5mM DMOG. At 1 and 2mM, DMOG
caused 83 and 93% increase, respectively, in the protein level. A
higher concentration of DMOG did not cause further increase
in the HIF-1α level (data not shown), indicating that inhibition
of hydroxylation by DMOG at 2mM is close to its maximal
effect. Taken together, these data suggested that inhibiting the
proteasomes with MG-132 stabilized the HIF-1α level more than
DMOG did under the OGD condition.
Next we treated the neurons with a combination of both a
proteasome inhibitor (40µM MG-132 or 8µM Epox) and the
prolyl hydroxylase inhibitor, DMOG (2mM). Neuronal viability
was significantly increased with the combination treatment
compared to the control normoxic conditions, OGD, and the
individual drug treatments (Figure 2C).
Western blot analysis also showed that the combined drug
treatments lead to a greater stabilization of HIF-1α (Figure 2D).
Immunoblotting analysis for hydroxylated HIF-1α (HIF-OH)
confirmed that DMOG reduced hydroxylation of HIF-1α. The
level of HIF-OH was highest under normoxia. It was decreased
under OGD exposure and slightly increased with the inhibition
of the proteasomes. The combined drug treatment resulted in
HIF-OH levels that were more than that of the DMOG treatment
only but still lower than that with the proteasome inhibitors
alone.
Proteasomal Inhibition Is More Effective
than PHD Inhibition in Reducing Brain
Infarct Size in an In vivo Stroke Model
We then evaluated effects of proteasomal inhibition and
hydroxylase inhibition on brain damage in an in vivo mouse
stroke model. Adult male mice were subjected to MCAO
followed by a 24 h period of reperfusion. Four animal groups
were examined: (1) Control, (2) Epox, (3) DMOG, and (4)
Epox + DMOG. Epox was chosen as the proteasome inhibitor
for the in vivo studies because it is able to cross the blood-brain
barrier (Stefanis and Keller, 2007). It is also more selective and
potent than MG-132. Epox was administered at 1.1mg/kg/0.1
cc as reported previously (Meng et al., 1999). DMOG was
administered at 50mg/kg/0.1 cc to inhibit the PHD (Ogle et al.,
2012). The results revealed that Epox was more effective at
reducing infarct size compared to DMOG (Figure 3B). The brain
images demonstrating the ischemic infarct from all analyzed
animals are shown in Supplementary Figure 2. We also assessed
the infarct size following MCAO with the pretreatment with
higher concentrations of DMOG to ensure that a sufficient
amount of DMOG was given to the mice to inhibit the PHD
(Supplementary Figure 3). Epox was more effective than the
increased concentrations of DMOG. Brain edema volume was
also measured from the coronal sections. As shown in Figure 3C,
all 3 drug-treated animal groups had a significant decrease in
edema volume following MCAO compared to the control mice.
However, there was no significant difference between the groups.
Furthermore, immunoblotting showed that HIF-1α protein levels
were increased in the ipsilateral hemisphere and that it is
significantly stabilized with the combined administration of Epox
and DMOG.
DISCUSSION
The induction of HIF-1 is very important following cerebral
ischemia. Dimerization of HIF-1α to HIF-1β leads to the
expression of various genes that can promote cellular adaptation
to conditions of low oxygen. Its targets include genes that
code for molecules that participate in vasomotor control,
angiogenesis, erythropoiesis, cell proliferation, and energy
metabolism (Semenza, 2003a,b; Sharp and Bernaudin, 2004).
Each of these functions potentially contributes to the survival
of neuronal cells at hypoxic conditions. Neuron-specific HIF-
1 deficient mice showed increased brain damage following
MCAO (Baranova et al., 2007). In this study, we investigated the
mechanisms of HIF-1α degradation in ischemic neurons. The
results for the first time demonstrated that both 20S and 26S
proteasomal pathways were involved in HIF-1α degradation in
ischemic neurons. The results provide important information
for not only understanding the pathophysiology of cerebral
ischemia but also designing potential strategies for stroke
treatment.
Under normoxic conditions, HIF-1α is rapidly degraded
via the ubiquitin-dependent proteasomal (26S) degradation
pathway after hydroxylation and ubiquitination. Under hypoxic
conditions, it is generally regarded that HIF-1α is accumulated
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FIGURE 2 | HIF-1α protein stabilization with the treatments of proteasome or PHD inhibitors. (A) Immunoblotting showing HIF-1α protein levels in neurons
and (B) the quantitative results for Western blot data. Equalization of protein loading was determined using β-actin as the housekeeping protein. *p < 0.05 vs.
normoxia (N), ∧p < 0.05 vs. oxygen/glucose deprivation (OGD) (n = 3). (C) Neuronal viability assessed using the MTT assay *p < 0.05 vs. OGD, #p < 0.05 vs.
DMOG (n = 3). (D) Immunoblotting showing HIF-1α and hydroxyl-HIF-1α (HIF-OH) protein levels in neurons. Equalization of protein loading was determined using
β-actin as the housekeeping protein. Quantitative results for Western blot data. *p < 0.05 vs. N, #p < 0.05 vs. OGD (n = 3).
due to hydroxylation inhibition (Jiang et al., 1996; Wood et al.,
1996; Salceda and Caro, 1997; Huang et al., 1998; Kallio et al.,
1999; Huang and Bunn, 2003). Our experimental results from
PHD inhibition suggest that the 26S proteasomal pathway
contributed to the degradation of HIF-1α in ischemia, at least in
our experimental setting, indicating that PHD activity was not
completed suppressed at the low oxygen conditions. Besides the
26S pathway, there are other pathways, such as 20S, that may
cause HIF-1α degradation. For HIF-1α to be a target of the 20S
proteasomes it would have to be oxidized as the 20S preferably
degrades oxidized protein. HIF-1α was found to be an oxidizable
protein soon after it was discovered (Wang et al., 1995b; Huang
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FIGURE 3 | Effect of DMOG and epoxomicin (Epox) on HIF-1α expression and brain damage induced by cerebral ischemia. Brain damage as determined
by TCC staining after mice were subjected to 90 min ischemia followed by 24 h reperfusion. (A) Representative TTC staining of brain coronal sections taken from the
3mm position of the frontal pole. (B) Quantification of infarct volume determined by TTC stained sections (n = 5). Data presented as means ± SEM *p < 0.05, vs.
control untreated mice. #p < 0.05, vs. mice treated with Epox. (C) Quantification of brain edema volume estimated from TTC stained sections (n = 5). Data
presented as means ± SEM *p < 0.05, vs. control untreated mice. (D) Immunoblotting showing the levels of HIF-1α from the ipsilateral brain hemispheres of
untreated mice and mice treated with dimethyloxalylglycine (DMOG), Epox or a combination of both (n = 3).
et al., 1996) due to its residues with redox properties such
as cysteine and methionine. Oxidative modification of cellular
proteins was reported to occur within 10min and peak at 1 or
2 h after the ischemic insults (Oliver et al., 1990; Hall et al., 1995).
Yet, it is not known which residue of HIF-1α is oxidized by
ischemia. Our observation that proteasomal inhibition increased
HIF-1α levels more than a PHD inhibitor could under a low O2
condition is in accordance with a previous report (Demidenko
et al., 2005). These results indicate that HIF-1α is, at least partly,
degraded via a hydroxylation-independent proteasome pathway,
and suggest that besides 26S, the 20S proteasome is involved in
the degradation of HIF-1α under hypoxia.
Ischemia induces a rapid accumulation of free iron the brain
(Palmer et al., 1999). Given that PHDs belong to a family of
enzymes that require iron as an essential cofactor, the increase
in the iron level elevates PHD activity. Under iron-lacking
conditions, PHDs are inactivated, preventing the ubiquitination
and proteasomal degradation of HIF-1α. In this aspect, the
neuroprotective effects of iron chelators such as desferoxamine
have been attributed to the activation of HIF-1 (Prass et al.,
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FIGURE 4 | Schematic diagram of HIF-1α degradation mechanisms.
Under normoxic conditions, HIF-1α is hydroxylated by prolyl hydroxylases
(PHD), which targets it for degradation via the 26S proteasome pathway.
During conditions of low oxygen and high oxidative stress, HIF-1α can be
oxidized and subsequently degraded by the 20S proteasome.
2002; Hamrick et al., 2005; Freret et al., 2006; Sorond et al.,
2015). Free iron plays a critical role in oxidative damage due to
the Fenton’s reaction where hydrogen peroxide is converted to
the highly reactive hydroxyl radical. Based on our results, it is
possible that iron chelators may also enhance HIF-1α expression
by inhibiting its oxidation and thus its degradation through
the 20S proteasomal pathway. Indeed, reduction of ROS by the
liposoluble iron chelator 2,2′-dipyridyl in a rat photothrombotic
ischemic stroke model was observed concomitantly with an
increase in the level of HIF-1α protein (Demidenko et al., 2005).
It is noteworthy to point out that proteasomal inhibitors
may protect the brain from ischemic injury by additional or
alternative mechanisms. For example, it has been reported that
the proteasome inhibitor MLN519 was neuroprotective against
stroke injuries by inhibiting the pro-inflammatory nuclear
factor-κB (Berti et al., 2003; Williams et al., 2003, 2004, 2005,
2006). Another proteasome inhibitor, bortezomib, was also
able to reduce post-ischemic inflammation (Henninger et al.,
2006; Zhang et al., 2010). Furthermore, a recent study by
Doeppner et al. (2012) showed that the intracerebral delivery of
BSc2118, a novel proteasome inhibitor, induced neuroprotection
following ischemia by decreasing blood brain barrier breakdown
and enhanced cell proliferation, neurogenesis and angiogenesis
(Li et al., 2016). They speculated that the stimulation of
angioneurogensis was most likely a consequence of HIF-1α
stabilization. This is because in contrast to the intracerebral
delivery of BSc2218, a systemic BSc2118 delivery did not affect
HIF-1α abundance and subsequently there was no stimulation
of angioneurogensis in the brain (Sorond et al., 2015). It is not
clear if epoxomicin has additional functions besides inhibiting
proteasomal activities. The application of proteasome inhibitors
in this study was mainly to investigate the mechanism of ROS
mediated HIF-1α degradation in neurons during ischemia. An
additional increase in HIF-1α levels when both the proteasome
and PHD are inhibited indicates a role of the 20S in HIF-
1α degradation (Figure 2D). We also found that the combined
treatment and the stabilization of HIF-1α were protective in
both the in vitro primary neuron ischemia model and in the in
vivo mouse stroke model in terms of maintaining cell viability
(Figure 2C) and in the reduction of infarct size (Figure 3).
Currently, PHD enzymes are being targeted for drug discovery
in the treatment of stroke. PHDs regulate the HIF-1α degradation
pathway by acting as oxygen sensors (Epstein et al., 2001).
Therefore, the inhibition of PHD leads to the activation of HIF
and its downstream genes. A recent report demonstrated that
neuronal inactivation of PHD2 is sufficient to improve stroke
recovery with improved histological and functional outcome
by increasing HIF-1 activity (Li et al., 2016). PHD inhibitors
have been shown to be protective when administered prior to
or upon reperfusion in brain ischemia models (Gidday et al.,
1994; Prass et al., 2002; Siddiq et al., 2005; Liu et al., 2009;
Ogle et al., 2012). However, our results suggest that inhibiting
PHD may only provide a partial effect because HIF-1α can be
degraded by other pathways such as the 20S proteasomes (see
Figure 2A). The results reported here reveal that not only the 26S
proteasomal pathway but also the 20S one are involved in HIF-1α
degradation (Figure 4). Thus, PHD inhibitors are not as effective
as the proteasome inhibitors because the PHD inhibitors block
hydroxylation of HIF-1α and the 26S pathway activity, but not
the 20S pathway.
CONCLUSIONS
In summary, HIF-1 plays an important role in the fate of ischemic
neurons. Understanding the mechanism of HIF-1 induction
is very important in determining its role in cerebral ischemia
and providing potential approaches to regulate its expression.
This proof-of-concept study demonstrate that ischemia can alter
proteasomal activities in neurons and that both 26S and 20S
proteasomal degradation pathways contribute to the HIF-1α
degradation. ROS consist of several unique species, which
have dramatically different reactivities and half-lives. Actions
of ROS on HIF-1α degradation may be through specific ROS,
rather than ROS in general. Understanding the different ROS
species involved will provide us with a better understanding
of the mechanisms. It will also help us design more effective
intervention strategies, such as efficient antioxidants, to inhibit
or remove the specific species. We also provide evidence that
the inhibition of proteasomal activity with MG-132 and Epox
restored the attenuated accumulation of HIF-1α that might
result from increased ROS and provided neuroprotection.
Regulating HIF-1α induction and the genes induced by HIF-1
under ischemia are highly promising therapeutic targets for
cerebral ischemia (Giaccia et al., 2003; Williams et al., 2004; Shi,
2009). Defining this mechanism for HIF-1α degradation will
make it possible to design more efficient agents for inhibiting
HIF-1α degradation and promoting its neuroprotective
properties.
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